Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016

  • ID: 4039999
  • Report
  • 47 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Eli Lilly and Company
  • Mallinckrodt Plc
  • Merck KGaA
  • Neumedicines Inc
  • MORE
Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016

Summary:

‘Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 12 Receptor (IL12R) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 12 Receptor (IL12R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Interleukin 12 Receptor (IL12R) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
Certain sections in the report may be removed or altered based on the availability and relevance of data.
Updated report will be delivered in 48 hours of order confirmation.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Interleukin 12 Receptor (IL12R)
- The report reviews Interleukin 12 Receptor (IL12R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 12 Receptor (IL12R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 12 Receptor (IL12R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 12 Receptor (IL12R) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 12 Receptor (IL12R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 12 Receptor (IL12R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eli Lilly and Company
  • Mallinckrodt Plc
  • Merck KGaA
  • Neumedicines Inc
  • MORE
Introduction

Interleukin 12 Receptor (IL12R) Overview

Therapeutics Development

Interleukin 12 Receptor (IL12R) - Products under Development by Stage of Development

Interleukin 12 Receptor (IL12R) - Products under Development by Therapy Area

Interleukin 12 Receptor (IL12R) - Products under Development by Indication

Interleukin 12 Receptor (IL12R) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Interleukin 12 Receptor (IL12R) - Products under Development by Companies

Interleukin 12 Receptor (IL12R) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 12 Receptor (IL12R) - Companies Involved in Therapeutics Development

Eli Lilly and Company

Mallinckrodt Plc

Merck KGaA

Neumedicines Inc

Interleukin 12 Receptor (IL12R) - Drug Profiles

Cellular Immunotherapy to Activate Interleukin-12 for Skin Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edodekin alfa SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3232094 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-9241 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMIL-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 12 Receptor (IL12R) - Dormant Projects

Interleukin 12 Receptor (IL12R) - Discontinued Products

Interleukin 12 Receptor (IL12R) - Featured News & Press Releases

Mar 02, 2015: Department of Defense Supports Neumedicines With Groundbreaking Grant for Surgical Site Infection Therapy

Apr 28, 2014: Phase I Clinical Study of Neumedicines' Interleukin-12 as a Treatment for Wound Healing and Infections Recommended for Funding by the U.S. Department of Defense

Apr 18, 2014: Neumedicines Publishes Clinical Data Demonstrating Safety and Hematopoietic and Immune Effects of HemaMax (rHuIL-12), a Radiation Medical Countermeasure

Apr 15, 2014: Neumedicines Announces Publication of Phase II-Equivalent Data Demonstrating the Survival Effect of HemaMax (rHuIL-12), a Radiation Medical Countermeasure

Jan 09, 2014: Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference

Dec 13, 2013: Neumedicines Presents HemaMax Clinical Data at the ASH Conference

Jun 10, 2013: Neumedicines Receives $8.3m Award From BARDA For Continued Development Of HemaMax As Countermeasure To Acute Radiation Exposure

May 14, 2013: Neumedicines Receives BARDA Notification Of Intent To Exercise Contract Option To Continue Development Of HemaMax As Radiation Medical Countermeasure

Jan 25, 2013: Neumedicines Presents Data On HemaMax At BARDA And NIAID Sponsored Symposium

Jul 23, 2012: TherapyX Partners with Neumedicines

May 05, 2012: Neumedicines's HemaMax Demonstrates Unprecedented Survivability After Lethal Dose Of Radiation In Mice And Non-Human Primates

Mar 05, 2012: Neumedicines’s HemaMax Demonstrates Positive Preclinical Results After Lethal Dose Of Radiation In Mice And Non-Human Primates

Sep 27, 2011: Neumedicines Wins US Federal Government Contract Up To $273m To Fund Late-Stage Development Of HemaMax

Jan 31, 2011: Neumedicines Receives Notice Of Allowance For Patent Covering Use Of HemaMax To Treat Chemotherapy-Induced Thrombocytopenia

Aug 12, 2010: Neumedicines Receives $2.5 Million From HHS/BARDA After Successful Non-Human Primate Studies to Further Advance HemaMax As a Radiation Countermeasure

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Eli Lilly and Company, H2 2016

Pipeline by Mallinckrodt Plc, H2 2016

Pipeline by Merck KGaA, H2 2016

Pipeline by Neumedicines Inc, H2 2016

Dormant Projects, H2 2016

Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Eli Lilly and Company
  • Mallinckrodt Plc
  • Merck KGaA
  • Neumedicines Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll